Shukra Pharmaceuticals Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 13, 2026

Key Highlights

The Latest Trading Price of Shukra Pharmaceuticals Ltd is ₹ 31.79 as of 13 May 15:30 . The P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 31 on March 2025 . This represents a CAGR of -9.49% over 4 years The Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 1546 crore on March 2025 . This represents a CAGR of 13.96% over 4 years The revenue of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 7.27 crore as compare to the Dec '25 revenue of ₹ 39.95 crore. This represent the decline of -81.8% The revenue of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 120.64 crore. This represent the decline of -100% The ebitda of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 1.65 crore as compare to the Dec '25 ebitda of ₹ 27.95 crore. This represent the decline of -94.1% The ebitda of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 26.71 crore. This represent the decline of -100% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ -1.72 crore over 6 quarters. This represents a CAGR of NaN% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Shukra Pharmaceuticals Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Shukra Pharmaceuticals Ltd or Syncom Formulations (India) Ltd?

Market cap of Shukra Pharmaceuticals Ltd is 1,392 Cr while Market cap of Syncom Formulations (India) Ltd is 1,292 Cr

What are the key factors driving the stock performance of Shukra Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

The stock performance of Shukra Pharmaceuticals Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Shukra Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

As of May 13, 2026, the Shukra Pharmaceuticals Ltd stock price is INR ₹31.79. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹13.75.

How do dividend payouts of Shukra Pharmaceuticals Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Shukra Pharmaceuticals Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.